Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2016
At a glance
- Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Chronic lymphocytic leukaemia; Lymphocytosis
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 13 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 08 Jan 2016 Planned number of patients changed from 76 to 58 as reported by ClinicalTrials.gov record.